Intra-Cellular Therapies' GAAP loss for 2020 was $227.006 million, up 53.7% from $147.722 million the prior year. Revenue increased multiple times to $22.813 million from $0.061 million a year earlier.
Intra-Cellular Therapies' GAAP loss for 2020 was $227.006 million, up 53.7% from $147.722 million the prior year. Revenue increased multiple times to $22.813 million from $0.061 million a year earlier. 
ir.intracellulartherapies.com
English (US) 